Evidence map›Paper›PMID 41100914›Full record

GuidelineGynecologic oncology2025

Interstitial lung disease in targeted therapies: A Society of Gynecologic Oncology clinical practice statement.

Charles A Powell, Ira S Winer, Christopher M Tarney, Stéphanie Gaillard, Róisín E O'Cearbhaill

Abstract readPractice GuidelineReview
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Gynecologic oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Charles A PowellDivision of Pulmonary, Critical Care and Sleep Medicine, Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: charles.powell@mssm.edu.
Ira S WinerKarmanos Cancer Institute and Wayne State University, Detroit, MI, USA.
Christopher M TarneyGynecologic Cancer Center of Excellence, Department of Gynecologic Surgery & Obstetrics, Walter Reed National Military Medical Center, Bethesda, MD, USA.
Stéphanie GaillardJohns Hopkins School of Medicine, Baltimore, MD, USA.
Róisín E O'CearbhaillDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
THE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4M
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA196521
6 · The paper itself

Abstract

Interstitial lung disease (ILD) is a potentially serious and sometimes fatal complication of targeted therapies, including antibody-drug conjugates and immunotherapies, in gynecologic oncology. Risk factors include pre-existing lung disease, advanced age and prior thoracic radiation. Early detection, patient and clinician education, and prompt multidisciplinary collaboration are critical to mitigate ILD morbidity and mortality. This Society of Gynecologic Oncology clinical practice statement provides evidence-based recommendations for the diagnosis, grading and management of ILD associated with gynecologic cancer therapies, emphasizing the importance of baseline risk assessment, ongoing monitoring and standardized intervention protocols to optimize patient outcomes.

Indexed as

Genital Neoplasms, FemaleLung Diseases, InterstitialMolecular Targeted TherapyFemaleHumansRisk FactorsAnti-neoplastic therapy and emerging therapiesDrug-induced lung injuryInterstitial lung disease (ILD)Pneumonitis

Identifiers

PMID41100914
PMCPMC12611096

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.